Vident Investment Advisory’s Burning Rock Biotech BNR Stock Holding History

Vident Investment Advisory’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,532	Closed	-$32.9K	–	146
2023 Q2	$32.9K	Sell	1,532 -1,556	-50%	-$41.3K	﹤0.01%	1160
2023 Q1	$86.8K	Buy	3,088 +167	+6%	+$5K	﹤0.01%	1175
2022 Q4	$65.7K	Buy	2,921 +219	+8%	+$5K	﹤0.01%	1132
2022 Q3	$48K	Buy	2,702 +1,576	+140%	+$50.9K	﹤0.01%	1099
2022 Q2	$33K	Buy	+1,126	New	+$50.3K	﹤0.01%	1252
2021 Q4	–	Sell	-1,049	Closed	-$188K	–	1206
2021 Q3	$188K	Buy	1,049 +204	+24%	+$45.3K	0.01%	1091
2021 Q2	$249K	Hold	845	–	–	0.01%	982
2021 Q1	$227K	Sell	845 -192	-19%	-$58.4K	0.01%	952
2020 Q4	$240K	Sell	1,037 -5	-0.5%	-$1.34K	0.01%	851
2020 Q3	$261K	Buy	+1,042	New	+$247K	0.01%	790

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vident Investment Advisory's BNR Position: Q3 2023 in Review

Vident Investment Advisory sold out of Burning Rock Biotech (BNR) in Q3 2023, closing a stake of 1,532 shares — an estimated $32.9K sold.

Vident Investment Advisory first reported a position in BNR in Q3 2020 and held it in 10 quarters. The position peaked at $261K in Q3 2020. 28 funds tracked by Wall St. Rank hold BNR as of Q3 2023.

Vident Investment Advisory reported no remaining Burning Rock Biotech position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 1,532 Burning Rock Biotech shares in Q3 2023, an estimated $32.9K.
Vident Investment Advisory first reported a position in Burning Rock Biotech in Q3 2020 and held it in 10 quarters.
Vident Investment Advisory's Burning Rock Biotech position peaked at $261K in Q3 2020.
28 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.